Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients

New Microbiologica

Volumn 34, Issue 3, 2011, Pages 317-321

  Morsica, Giulia ^a   Bianchi, Giampaolo ^b   Bagaglio, Sabrina ^a   Conte, Camilla ^b   Salpietro, Stefania ^a   Porrino, Lucy ^a   Uberti Foppa, Caterina ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Darunavir; HCV; HIV; Liver toxicity; Ritonavir

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; DRUG EFFECT; ENZYMOLOGY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITONAVIR;

HEPATITIS C VIRUS;

EID: 84860415854     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Aceti A., Pasquazzi c., Zechini B., De Bac c. Liverhaart Group. (2002). Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and c virus infection. J. Acquir. Immune Defic. Syndr. 29, 41-48. (Pubitemid 34094305)
2. Aids Clinical Trials Group. Division of AIDS table for grading severity of adult adverse experiences-August 1992. Available at: http://rcc.techres.com/ DAIDS%20RCC%Forms/ToxicityTableAdult-TRP-v01a.pdf. Accessed, May, 8, 2010.
3. French A.L., Benning L., Anastos K., Augenbraun M, Nowicki M., Sathasivam K., Terrault N.A. (2004). Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin. Infect. Dis. 39, 402-410. (Pubitemid 39050490)
4. Katlama C., Esposito R., Gatell J.M., Goffard J.C., Grinsztejn B., Pozniak A., Rockstroh J., Stoehr A., Vetter N., Yeni P., Parys W., Vangeneugden T.; Power 1 Study Group. (2007). Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 21, 395- 402.
5. Meraviglia P., Schiavini M., Castagna A., Viganoà P., Bini T., Landonio S., Danise A., Moiou M.C., Angeu E., Bongiovanni M., Hasson H, Duca P., Cargnel A. (2004). Lopinavir/ritonavir treatment in HIV anti-retroviral- experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Med. 5, 334-343. (Pubitemid 39276331)
6. Puon M., Torti C., Ripamonti D., Castelli E, Zaltron S., Zanini B., Spinetti A., Putzolu V., Casari S., Tomasoni L., Quiros-Roldan E., Favret M., Berchich L., Grigolato P., Callea F., Carosi G.; Hiv- Hcv Co-Infection Study Group. (2003). Severe hepatotoxicity during combination antiretroviral treat-ment: incidence, liver histology, and outcome. J. Acquir. Immune Defic. Syndr. 32, 259-267. (Pubitemid 36331697)
7. Rachus A., Clotet B., Baxter J., Murphy R., Lefebvre E. (2007). Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV. Clin. Trials. 8, 213- 220. (Pubitemid 47327458)
8. Savès M., Raffi E, Clevenbergh P., Marchou B., Waldner-Combernoux A., Morlat P., Le Moing V., Rivière C., CHêNE G., Leport C. (2000). Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob. Agents. Chemother. 44, 3451-3455. (Pubitemid 33009512)
9. Sulkowski M.S., Thomas D.L., Chaisson R.E., Moore R.D. (a 2000). Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 283, 74-80. (Pubitemid 30038386)
10. Sulkowski M.S., Mehta S.H., Chaisson R.E., Thomas D.L., Moore R.D. (b 2004). Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 18, 2277-2284. (Pubitemid 39620220)